CXCR

シグナル伝達経路

研究分野

阻害剤の選択性比較

カタログ番号 製品カタログ 溶解度(25°C)
DMSO アルコール
S3951 Tannic acid -1 mg/mL 100 mg/mL -1 mg/mL
S8640 Reparixin (Repertaxin) <1 mg/mL 56 mg/mL 56 mg/mL
S3013 Plerixafor 8HCl (AMD3100 8HCl) 100 mg/mL <1 mg/mL <1 mg/mL
S8030 Plerixafor (AMD3100) 3 mg/mL <1 mg/mL 100 mg/mL
S2912 WZ811 <1 mg/mL 30 mg/mL <1 mg/mL
S2879 AMD3465 hexahydrobromide 98 mg/mL 2 mg/mL <1 mg/mL
S8506 SCH-527123 <1 mg/mL 79 mg/mL 79 mg/mL
S6617 MSX-122 <1 mg/mL 3 mg/mL <1 mg/mL
S6620 Danirixin (GSK1325756) <1 mg/mL 88 mg/mL <1 mg/mL
S8813 LIT-927 <1 mg/mL 66 mg/mL <1 mg/mL
S7651 SB225002 <1 mg/mL 70 mg/mL 3 mg/mL
S8309 ATI-2341 <1 mg/mL 100 mg/mL 2 mg/mL
S8869 UNBS5162 <1 mg/mL 17 mg/mL <1 mg/mL

亜型選択性的な製品

CXCR製品

新CXCR製品
製品コード 製品説明 文献中Selleckの製品使用例 お客様のフィードバック
S3951

Tannic acid

Tannic acid, a polyphenolic compound, is a CXCL12/CXCR4 inhibitor with antiangiogenic, anti-inflammatory and antitumor activity.

S8640

Reparixin (Repertaxin)

Reparixin(Repertaxin) is a inhibitor of human CXCR1/R2 and rat CXCR2 receptor activation. It also inhibits human CXCL8 receptor activation.

S3013

Plerixafor 8HCl (AMD3100 8HCl)

Plerixafor 8HCl (AMD3100 8HCl) is the hydrochloride of Plerixafor, a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM in cell-free assays, respectively.

S8030

Plerixafor (AMD3100)

Plerixafor (AMD3100) is a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM in cell-free assays, respectively.

S2912

WZ811

WZ811 is a highly potent competitive CXCR4 antagonist with EC50 of 0.3 nM.

S2879

AMD3465 hexahydrobromide

AMD3465 is a monomacrocyclic CXCR4 antagonist.

S8506

SCH-527123

SCH-527123 is a potent, orally bioavailable CXCR2/CXCR1 antagonist with IC50 values of 2.6 nM and 36 nM, respectively.

S6617

MSX-122

MSX-122 is a novel small molecule and partial CXCR4 antagonist (IC50~10 nM).

S6620

Danirixin (GSK1325756)

Danirixin (GSK1325756) is a small molecule, non-peptide, high affinity (IC50 for CXCL8 binding = 12.5 nM), selective, and reversible CXCR2 antagonist.

S8813

LIT-927

LIT-927 is a novel neutraligand of CXCL12 with Ki value of 267 nM for inhibition of Texas red-labeled CXCL12 (CXCL12-TR) binding. It shows high selectivity toward CXCL12 vs other chemokines also involved in asthma.

S7651

SB225002

SB225002 is a potent, and selective CXCR2 antagonist with IC50 of 22 nM for inhibiting interleukin IL-8 binding to CXCR2, > 150-fold selectivity over the other 7-TMRs tested.

S8309

ATI-2341

ATI-2341, pepducin targeting the C-X-C chemokine receptor type 4 (CXCR4), is an allosteric agonist activating the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization.

S8869

UNBS5162

UNBS5162 is a pan-antagonist of CXCL chemokine expression with in vitro cytotoxic activity (IC50 range of 0.5-5 µM) against a range of human cancer cell lines including glioblastoma (Hs683 and U373MG), colorectal (HCT-15 and LoVo), non-small-cell lung (A549) and breast (MCF-7).

製品コード 製品説明 文献中Selleckの製品使用例 お客様のフィードバック
S3951

Tannic acid

Tannic acid, a polyphenolic compound, is a CXCL12/CXCR4 inhibitor with antiangiogenic, anti-inflammatory and antitumor activity.

S8640

Reparixin (Repertaxin)

Reparixin(Repertaxin) is a inhibitor of human CXCR1/R2 and rat CXCR2 receptor activation. It also inhibits human CXCL8 receptor activation.

製品コード 製品説明 文献中Selleckの製品使用例 お客様のフィードバック
S3013

Plerixafor 8HCl (AMD3100 8HCl)

Plerixafor 8HCl (AMD3100 8HCl) is the hydrochloride of Plerixafor, a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM in cell-free assays, respectively.

2019, 101(1):102-111

2016, 10.3390/ijms17060943

2016, 48(5):2098-112

S8030

Plerixafor (AMD3100)

Plerixafor (AMD3100) is a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM in cell-free assays, respectively.

2019, 10(3):191

2019, 20(2):1203-1211

2018, 8(2):369-383

S2912

WZ811

WZ811 is a highly potent competitive CXCR4 antagonist with EC50 of 0.3 nM.

2018, 315(3):L404-L421

2018, 9(6):929-940

2018, 59(6):1451-1460

S2879

AMD3465 hexahydrobromide

AMD3465 is a monomacrocyclic CXCR4 antagonist.

S8506

SCH-527123

SCH-527123 is a potent, orally bioavailable CXCR2/CXCR1 antagonist with IC50 values of 2.6 nM and 36 nM, respectively.

S6617

MSX-122

MSX-122 is a novel small molecule and partial CXCR4 antagonist (IC50~10 nM).

S6620

Danirixin (GSK1325756)

Danirixin (GSK1325756) is a small molecule, non-peptide, high affinity (IC50 for CXCL8 binding = 12.5 nM), selective, and reversible CXCR2 antagonist.

2019, 9(18):5332-5346

S8813

LIT-927

LIT-927 is a novel neutraligand of CXCL12 with Ki value of 267 nM for inhibition of Texas red-labeled CXCL12 (CXCL12-TR) binding. It shows high selectivity toward CXCL12 vs other chemokines also involved in asthma.

S7651

SB225002

SB225002 is a potent, and selective CXCR2 antagonist with IC50 of 22 nM for inhibiting interleukin IL-8 binding to CXCR2, > 150-fold selectivity over the other 7-TMRs tested.

2019, 9(18):5332-5346

2019, 19:64

2019, 54(5):1555-1566

製品コード 製品説明 文献中Selleckの製品使用例 お客様のフィードバック
S8309

ATI-2341

ATI-2341, pepducin targeting the C-X-C chemokine receptor type 4 (CXCR4), is an allosteric agonist activating the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization.

製品コード 製品説明 文献中Selleckの製品使用例 お客様のフィードバック
S8869

UNBS5162

UNBS5162 is a pan-antagonist of CXCL chemokine expression with in vitro cytotoxic activity (IC50 range of 0.5-5 µM) against a range of human cancer cell lines including glioblastoma (Hs683 and U373MG), colorectal (HCT-15 and LoVo), non-small-cell lung (A549) and breast (MCF-7).